Cola as a quick fix for esophageal blockages in cancer patients?
NCT ID NCT06652620
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether drinking cola can help relieve sudden food blockages in the esophagus for people with esophageal cancer. Fifty participants will be randomly assigned to drink cola or receive standard care, and researchers will check if the blockage clears within 24 hours. The goal is to find a simple, non-invasive way to manage this common and distressing problem.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cola (Coca-Cola or Pepsi-Cola)
- What this could lead to
- If it works, this could provide a simple, at-home remedy to quickly relieve food blockages in esophageal cancer patients, avoiding emergency procedures.
- What could go wrong
- This is a small, early-stage trial with only 50 participants, so results may not apply to everyone. Cola might not work for all blockages, and there is a risk of aspiration or worsening symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with primary esophageal lesions diagnosed by pathology, being able to consume at least a liquid diet normally before and diagnosed by a physician with acute esophageal impaction (acute esophageal impaction refers to the sudden occurrence of complete obstruction of eating within the past week) 2. Prior to enrollment, the patient did not consume carbonated beverages such as cola, or any other treatment for esophageal impaction. 3. Age ≥ 18 years old, Eastern Cooperative Oncology Group (ECOG) Performance Status score is 0-2 points. 4. The subjects voluntarily enrolled and obtained an informed consent form signed by the patient or their legal representative. Exclusion Criteria: 1. It is known that complete esophageal obstruction is caused by tumor progression. 2. Patients who have been diagnosed with or highly suspected of having esophageal fistula through endoscopy or imaging prior to enrollment. 3. Patients with nasogastric nutrition tube and esophageal stent implantation 4. Patients who have symptoms such as coughing and are unable to drink cola, or who are at serious risk of aspiration (Glasgow Coma Scale\<14 or previous history of aspiration). 5. Benign diseases such as gastroesophageal reflux, cardiac arrest, and congenital esophageal stenosis that can easily lead to foreign body impaction in the esophagus. 6. Patients with coagulation dysfunction, thrombocytopenia, or taking anticoagulant drugs that are medically considered contraindications for endoscopic examination and treatment. 7. According to the researchers' assessment, patients may not be able to cooperate with the examination and treatment, or there may be other factors that could force them to terminate the study midway, such as having other serious illnesses (including mental illnesses) that require concomitant treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the patients or the collection of experimental data.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First People's Hospital
Jingdezhen, Jiangxi, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Fudan University Shanghai Cancer Center Xiamen Hospital
Xiamen, Fujian, China
-
The Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, 225001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?
- Can a new drug shrink tumors that resist standard care?